Skip to main content

Table 1 Baseline characteristics in chronic diseases patients and the rest of the population

From: The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population

  COPD n (%) OA n (%) RA n (%) CKD n (%) DM n (%) The rest of the population n (%)
  PP SP PP SP PP SP PP SP PP SP PP SP
Statin-exposed 617(48.4) 292(65.9) 696(54.8) 175(70.9) 181(42.1) 60(76.9) 442(44.3) 386(54.8) 4101(68.5) 514(72.1) 4574(57.4) 1315(86.6)
Age (years) (mean SD) 68.5(8.8) 70.2(9.0) 68.5(8.9) 70.8(9.6) 63.9(11.5) 68.1(9.9) 66.7(14.1) 73.6(10.5) 60.9(11.8) 67.3(10.5) 64.2(11.1) 67.1(10.9)
Male 297(48.1) 169(57.9) 295(42.5) 95(54.6) 46(25.4) 29(48.3) 248(56.4) 239(62.2) 2079(51.1) 323(63.0) 2182(47.7) 824(62.7)
Baseline TC (mmol/L) (mean SD) 5.30(1.20) 4.68(1.10) 5.30(1.19) 4.54(1.07) 5.54(1.10) 4.95(1.28) 5.11(1.40) 4.85(1.44) 5.90(1.26) 5.20(1.36) 6.03(1.26) 5.28(1.13)
Simvastatin daily dose (mg) (mean SD) 29(19) 29(20) 27(16) 35(27) 28(18) 33(25) 27(18) 26(17) 27(16) 30(24) 28(19) 30(22)
Social economic status
  1 (most deprived) 285(46.1) 126(43.2) 141(20.3) 50(28.6) 46(25.4) 18(30.0) 108(25.2) 106(28.5) 1015(25.5) 125(24.9) 837(18.7) 322(25.1)
  2-4 254(42.1) 130(45.2 402(58.9) 90(52.6) 100(56.8) 35(58.3) 244(56.9) 210(56.9) 2275(57.1) 310(61.6) 2681(59.8) 760(59.1)
  5 (most affluent) 64(10.4) 31(10.6) 139(20.0) 31(17.7) 30(16.6) 7(11.7) 77(18.0) 56(15.1) 693(17.4) 68(13.5) 964(21.5) 203(15.8)
Concurrent use of drugs
  Analgesics 453(73.4) 222(76.0) 591(84.9) 156(89.1) 153(84.5) 55(91.7) 303(68.6) 279(72.3) 2293(55.9) 335(65.2) 1897(41.5) 666(50.7)
  Positive inotropic drugs 30(4.9) 49(16.8) 17(2.4) 6(3.4) 3(1.7) 7(11.7) 40(9.1) 89(23.1) 174(4.2) 76(14.8) 106(2.3) 62(4.7)
  Diuretics 386(62.6) 183(62.7) 416(59.8) 100(57.1) 97(53.6) 39(65.0) 313(70.8) 311(80.6) 1932(47.1) 325(63.2) 2082(45.5) 569(43.3)
  Beta-adrenoceptor   blocking drugs 97(15.7) 78(26.7) 290(41.7) 94(53.7) 57(31.5) 41(68.3) 204(46.2) 208(53.9) 1456(35.5) 299(58.2) 1816(39.7) 776(59.0)
  Hypertension and   heart failure 373(60.5) 213(73.0) 431(61.9) 124(70.9) 82(45.3) 48(80.0) 303(68.6) 272(70.5) 2712(66.1) 390(75.9) 2135(46.7) 781(59.4)
  Nitrates & calcium-channel blockers 393(63.7) 235(80.5) 415(59.6) 130(74.3) 99(54.7) 51(85.0) 301(68.1) 302(78.2) 1951(47.6) 390(72.9) 2202(48.1) 947(72.0)
  Anticoagulants 43(7.0) 49(16.8) 56(8.1) 13(7.4) 13(7.2) 13(21.7) 64(14.5) 104(26.9) 237(5.8) 103(20.0) 227(4.9) 97(7.4)
  Antiplatelet drugs 400(64.8) 244(83.6) 423(60.8) 152(86.9) 93(51.4) 45(75.0) 242(54.8) 297(76.9) 2039(49.7) 421(81.9) 2329(50.9) 1107(84.2)
  Corticosteroids 457(74.1) 210(71.9) 208(29.9) 46(26.3) 109(60.2) 32(53.3) 163(36.9) 127(32.9) 1093(26.7) 148(28.8) 942(20.6) 260(19.8)
  NSAID drugs 180(29.2) 63(21.6) 342(49.1) 71(40.6) 110(60.8) 34(56.7) 91(20.6) 77(20.0) 1586(38.7) 166(32.3) 1292(28.3) 323(24.6)
Co-morbidity             
  Angina, TIA, heart failure 56(9.1) 142(48.6) 34(4.9) 17(9.7) 6(3.3) 9(15.0) 33(7.5) 140(36.3) 169(4.1) 109(21.2) 187(4.1) 508(38.6)
  Diabetes mellitus 111(18.0) 33(11.3) 131(18.8) 14(8.0) 36(19.9) 11(18.3) 67(15.2) 60(15.5) - - - -